Bristol Myers Squibb Stock Fundamentals
| BMY Stock | USD 48.93 0.63 1.30% |
Bristol Myers Squibb fundamentals help investors to digest information that contributes to Bristol Myers' financial success or failures. It also enables traders to predict the movement of Bristol Stock. The fundamental analysis module provides a way to measure Bristol Myers' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bristol Myers stock.
At this time, Bristol Myers' Net Income is fairly stable compared to the past year. Research Development is likely to rise to about 9.8 B in 2024, whereas EBIT is likely to drop slightly above 5.1 B in 2024. Bristol | Select Account or Indicator |
Bristol Myers Squibb Company Operating Margin Analysis
Bristol Myers' Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Bristol Myers Operating Margin | 0.17 % |
Most of Bristol Myers' fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bristol Myers Squibb is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Bristol Operating Margin Historical Pattern
Today, most investors in Bristol Myers Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Bristol Myers' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's operating margin growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Bristol Myers operating margin as a starting point in their analysis.
Bristol Myers Operating Margin |
| Timeline |
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Bristol Pretax Profit Margin
Pretax Profit Margin |
|
Based on the recorded statements, Bristol Myers Squibb has an Operating Margin of 0.1701%. This is 100.48% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The operating margin for all United States stocks is 103.09% lower than that of the firm.
Bristol Myers Squibb Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Bristol Myers's current stock value. Our valuation model uses many indicators to compare Bristol Myers value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Bristol Myers competition to find correlations between indicators driving Bristol Myers's intrinsic value. More Info.Bristol Myers Squibb is rated second in return on equity category among related companies. It is rated fifth in return on asset category among related companies reporting about 0.21 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Bristol Myers Squibb is roughly 4.71 . At this time, Bristol Myers' Return On Equity is fairly stable compared to the past year.Comparative valuation analysis is a catch-all model that can be used if you cannot value Bristol Myers by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Bristol Myers' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Bristol Myers' earnings, one of the primary drivers of an investment's value.Bristol Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bristol Myers' direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bristol Myers could also be used in its relative valuation, which is a method of valuing Bristol Myers by comparing valuation metrics of similar companies.Bristol Myers is currently under evaluation in operating margin category among related companies.
Bristol Myers ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Bristol Myers' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Bristol Myers' managers, analysts, and investors.Environment Score | Governance Score | Social Score |
Bristol Fundamentals
| Return On Equity | 0.27 | ||||
| Return On Asset | 0.0563 | ||||
| Profit Margin | 0.18 % | ||||
| Operating Margin | 0.17 % | ||||
| Current Valuation | 128.24 B | ||||
| Shares Outstanding | 2.03 B | ||||
| Shares Owned By Insiders | 0.10 % | ||||
| Shares Owned By Institutions | 78.98 % | ||||
| Number Of Shares Shorted | 35.12 M | ||||
| Price To Earning | 24.88 X | ||||
| Price To Book | 3.32 X | ||||
| Price To Sales | 2.17 X | ||||
| Revenue | 45.01 B | ||||
| Gross Profit | 36.38 B | ||||
| EBITDA | 19.18 B | ||||
| Net Income | 8.04 B | ||||
| Cash And Equivalents | 9.12 B | ||||
| Cash Per Share | 6.21 X | ||||
| Total Debt | 41.46 B | ||||
| Debt To Equity | 1.32 % | ||||
| Current Ratio | 1.42 X | ||||
| Book Value Per Share | 14.56 X | ||||
| Cash Flow From Operations | 13.86 B | ||||
| Short Ratio | 1.77 X | ||||
| Earnings Per Share | 3.86 X | ||||
| Price To Earnings To Growth | 2.24 X | ||||
| Target Price | 56.0 | ||||
| Number Of Employees | 34.1 K | ||||
| Beta | 0.39 | ||||
| Market Capitalization | 99.17 B | ||||
| Total Asset | 95.16 B | ||||
| Retained Earnings | 28.77 B | ||||
| Working Capital | 9.51 B | ||||
| Current Asset | 10.41 B | ||||
| Current Liabilities | 8.02 B | ||||
| Annual Yield | 0.05 % | ||||
| Five Year Return | 2.96 % | ||||
| Net Asset | 95.16 B | ||||
| Last Dividend Paid | 2.31 |
About Bristol Myers Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bristol Myers Squibb's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bristol Myers using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bristol Myers Squibb based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 4.2 B | 4.4 B | |
| Total Revenue | 45 B | 47.3 B | |
| Cost Of Revenue | 10.7 B | 5.8 B | |
| Stock Based Compensation To Revenue | 0.01 | 0.01 | |
| Sales General And Administrative To Revenue | 0.01 | 0.01 | |
| Research And Ddevelopement To Revenue | 0.21 | 0.14 | |
| Capex To Revenue | (0.03) | (0.03) | |
| Revenue Per Share | 21.75 | 22.84 | |
| Ebit Per Revenue | 0.38 | 0.25 |
Pair Trading with Bristol Myers
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bristol Myers position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bristol Myers will appreciate offsetting losses from the drop in the long position's value.Moving together with Bristol Stock
| 0.78 | A | Agilent Technologies Financial Report 28th of May 2024 | PairCorr |
| 0.63 | EQ | Equillium Financial Report 9th of May 2024 | PairCorr |
Moving against Bristol Stock
| 0.57 | KA | Kineta Inc Financial Report 9th of May 2024 | PairCorr |
| 0.56 | SABSW | SAB Biotherapeutics | PairCorr |
| 0.54 | DMTK | DermTech Financial Report 2nd of May 2024 | PairCorr |
| 0.49 | DRUG | Bright Minds Biosciences | PairCorr |
| 0.48 | ME | 23Andme Holding | PairCorr |
The ability to find closely correlated positions to Bristol Myers could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bristol Myers when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bristol Myers - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bristol Myers Squibb to buy it.
The correlation of Bristol Myers is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bristol Myers moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bristol Myers Squibb moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bristol Myers can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Bristol Myers Piotroski F Score and Bristol Myers Altman Z Score analysis. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Complementary Tools for Bristol Stock analysis
When running Bristol Myers' price analysis, check to measure Bristol Myers' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myers is operating at the current time. Most of Bristol Myers' value examination focuses on studying past and present price action to predict the probability of Bristol Myers' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bristol Myers' price. Additionally, you may evaluate how the addition of Bristol Myers to your portfolios can decrease your overall portfolio volatility.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |
Is Bristol Myers' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bristol Myers. If investors know Bristol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bristol Myers listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.09) | Dividend Share 2.31 | Earnings Share 3.86 | Revenue Per Share 21.753 | Quarterly Revenue Growth 0.006 |
The market value of Bristol Myers Squibb is measured differently than its book value, which is the value of Bristol that is recorded on the company's balance sheet. Investors also form their own opinion of Bristol Myers' value that differs from its market value or its book value, called intrinsic value, which is Bristol Myers' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bristol Myers' market value can be influenced by many factors that don't directly affect Bristol Myers' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bristol Myers' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bristol Myers is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bristol Myers' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.